Evidence map›Paper›PMID 39846584›Full record

ArticleGeriatrics (Basel, Switzerland)2025

Genetic Predisposition to Hippocampal Atrophy and Risk of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia.

Ioannis Liampas, Vasileios Siokas, Niki Mourtzi, Sokratis Charisis, Stefanos N Sampatakakis, Ioannis Foukarakis, Alex Hatzimanolis, Alfredo Ramirez, Jean-Charles Lambert, Mary Yannakoulia and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Geriatrics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Special Issue: The Role of Genetics in Dementia.International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ioannis LiampasDepartment of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41100 Larissa, Greece.ORCID 0000-0002-2958-5220
Vasileios SiokasDepartment of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41100 Larissa, Greece.
Niki Mourtzi1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.
Sokratis Charisis1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.
Stefanos N Sampatakakis1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.ORCID 0009-0009-7316-0471
Ioannis Foukarakis1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.
Alex HatzimanolisDepartment of Psychiatry, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.
Alfredo RamirezDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, 50923 Cologne, Germany.ORCID 0000-0003-4991-763X
Jean-Charles LambertU1167-RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liés au Vieillissement, CHU Lille, Inserm, Institut Pasteur de Lille, Université de Lille, 59000 Lille, France.
Mary YannakouliaDepartment of Nutrition and Dietetics, Harokopio University, 17671 Athens, Greece.ORCID 0000-0003-2171-7337
Mary H KosmidisLab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-8790-1220
Efthimios DardiotisDepartment of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41100 Larissa, Greece.ORCID 0000-0003-2957-641X
Georgios M HadjigeorgiouDepartment of Neurology, Medical School, University of Cyprus, Nicosia 2414, Cyprus.ORCID 0000-0001-5386-4273
Paraskevi SakkaAthens Association of Alzheimer's Disease and Related Disorders, 11636 Maroussi, Greece.
Konstantinos RouskasInstitute of Applied Biosciences, Centre for Research & Technology Hellas, 54124 Thessaloniki, Greece.ORCID 0000-0003-2549-6834
Nikolaos Scarmeas1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.

Funding

Alzheimer's Association IIRG-09-133014ESPA-EU program Excellence Grant (ARISTEIA) 189 10276/8/9/2011Ministry for Health and Social Solidarity (Greece) DY2b/oik.51657/14.4.2009
6 · The paper itself

Abstract

backgroundThere is a paucity of evidence on the association between genetic propensity for hippocampal atrophy with cognitive outcomes. Therefore, we examined the relationship of the polygenic risk score for hippocampal atrophy (PRShp) with the incidence of amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) as well as the rates of cognitive decline.

methodsParticipants were drawn from the population-based HELIAD cohort. Comprehensive neuropsychological assessments were performed at baseline and at follow-up. PRShp was derived from the summary statistics of a large genome-wide association study for hippocampal volume. Cox proportional hazards models as well as generalized estimating equations (GEEs) were used to evaluate the association of PRShp with the combined incidence of aMCI/AD and cognitive changes over time, respectively. All models were adjusted for age, sex, education, and apolipoprotein E (APOE) genotype.

resultsOur analysis included 618 older adults, among whom 73 developed aMCI/AD after an average follow-up of 2.96 ± 0.8 years. Each additional SD of PRShp elevated the relative hazard for incident aMCI/AD by 46%. Participants at the top quartile of PRShp had an almost three times higher risk of converting to aMCI/AD compared to the lowest quartile group. Higher PRShp scores were also linked to steeper global cognitive and memory decline. The impact of PRShp was greater among women and younger adults.

conclusionsOur findings support the association of PRShp with aMCI/AD incidence and with global cognitive and memory decline over time. The PRS association was sex- and age-dependent, suggesting that these factors should be considered in genetic modelling for AD.

Indexed as

Alzheimer’s diseasecognitive declinehippocampal atrophypolygenic risk score

Identifiers

PMID39846584
PMCPMC11755629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.